Aptevo Therapeutics (APVO) Names New Operations SVP

September 15, 2016 10:32 AM EDT
Get Alerts APVO Hot Sheet
Trade APVO Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Aptevo Therapeutics Inc. (Nasdaq: APVO) announced that Randy J. Maddux has joined the Company as Senior Vice President, Operations, effective July 2016. Mr. Maddux brings more than 30 years of biopharmaceutical operations experience and has served in key roles supporting the licensure and launch of several successful biopharmaceutical products, including, Avonex®, Tysabri®, Benlysta® and Raxibacumab.

“We are delighted to welcome Randy to the executive leadership team at Aptevo,” said Marvin White, President and Chief Executive Officer. “Randy’s expertise in protein therapeutic development and manufacturing is instrumental to our vision of developing and advancing novel immuno-oncology therapeutics based on our proprietary ADAPTIR™ bispecific antibody technology platform. We view ‘manufacturability’ and ‘stability’ as critical success factors for bispecific antibody platforms and consider these characteristics to be important differentiators for the ADAPTIR™ platform. Randy’s knowledge and leadership in the field will be invaluable as we develop and advance our ADAPTIR™ product candidates to address important unmet medical needs.”

In his new role at Aptevo, Mr. Maddux will work closely with the research, clinical and regulatory organizations to set strategic direction and provide operational support for the development of novel bispecific antibody candidates derived from Aptevo’s proprietary ADAPTIR™ platform. He will also provide oversight and direction in support of the supply chain for the Company’s four commercial products – IXINITY®, WINRHO®, HEPAGAM B® and VARIZIG®.

Prior to joining Aptevo, Mr. Maddux served as Vice President and Site Director at GlaxoSmithKline, where he led the largest biopharmaceutical development and manufacturing site within the GSK manufacturing network. Before that, Mr. Maddux served as Vice President of Manufacturing Operations at Human Genome Sciences, where he held executive responsibility for all activities associated with the manufacture of therapeutic proteins. Prior to joining Human Genome Sciences, Mr. Maddux held various leadership roles in operations and quality at Biogen and Glaxo. Mr. Maddux holds a M.B.A. from Duke University and a B.S. from East Carolina University.

Mr. White continued, “We are also pleased to announce the promotion of Jane Gross, Ph.D., to the position of Senior Vice President and Chief Scientific Officer. Jane has been instrumental in advancing the research and non-clinical development efforts for our ADAPTIR™ platform under our predecessor company, Emergent BioSolutions. Her expertise in immunology and protein therapeutics is an important asset as we strive to develop and advance novel immuno-oncology bispecific antibody candidates based on our ADAPTIR™ platform.”

Dr. Gross has a Ph.D. in immunology and over twenty-five years of experience in the discovery and development of novel protein therapeutics in autoimmune, infectious disease and oncology indications. Prior to joining Emergent, Dr. Gross served as Vice President of Immunology Research at ZymoGenetics Inc., where she led efforts directed at the discovery and development of therapeutics for the treatment of autoimmune disorders, infectious diseases and cancer.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Management Changes, Management Comments

Related Entities


Add Your Comment